Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

José Baselga, Mario Campone, Martine Piccart et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +9

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

Seock‐Ah Im, Yen‐Shen Lu, Aditya Bardia et al. · New England Journal of Medicine · 2019 · 1K citations · Full text

Medicine, Oncology, Pharmacology +15

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

George W. Sledge, Masakazu Toi, Patrick Neven et al. · JAMA Oncology · 2019 · 987 citations · Full text

Medicine, Oncology, Pharmacology +17

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · New England Journal of Medicine · 2019 · 841 citations · Full text

Medicine, Oncology, Pharmacology +14